Zijun Wang

Zijun Wang

Auto-generated profile, based on publicly available information

Zijun Wang

Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2024 in Journal of Medical Internet Research
Verified
Journal Article
Open access
XLXufei Luo
Xufei Luo
FCFengxian Chen
Fengxian Chen
DZDi Zhu
Di Zhu
LWLing Wang
Ling Wang
ZWZijun Wang
Zijun Wang
YCYaolong Chen
Yaolong Chen
Large language models (LLMs) such as ChatGPT have become widely applied in the field of medical research. In the process of conducting systematic reviews, similar tools can be used to expedite various steps, including defining clinical questions, performing the literature search, document screening, information extraction, and language refinement, thereby conserving resources and enhancing efficiency. However, when using LLMs, attention should be paid to transparent reporting, distinguishing between genuine and false content, and avoiding academic misconduct. In this viewpoint, we highlight the potential roles of LLMs in the creation of systematic reviews and meta-analyses, elucidating their advantages, limitations, and future research directions, aiming to provide insights and guidance for authors planning systematic reviews and meta-analyses.

19 May 2026 in Integrative Medicine Research
Verified
Journal Article
Open access
XLXufei Luo
Xufei Luo
BWBingyi Wang
Bingyi Wang
HLHui Liu
Hui Liu
KXKe Xu
Ke Xu
XYXuan Yu
Xuan Yu
ZBZhaoxiang Bian
Zhaoxiang Bian
Atopic dermatitis (AD) is a common chronic inflammatory skin disorder with substantial global burden. In some regions, Chinese medicine (CM) and integrated Chinese–Western medicine (ICWM) are widely used, but the overall clinical evidence remains unclear. This study aimed to systematically map and synthesize evidence on CM and ICWM for AD. A structured literature review was conducted using 14 predefined clinical questions to guide evidence mapping. CNKI, Wanfang Data, PubMed, Cochrane Database of Systematic Reviews, and CENTRAL were searched from inception to September 6, 2025. Included studies comprised clinical practice guidelines/consensus statements (CPGs/CSs), systematic reviews/meta-analyses (SR/MAs), and randomized controlled trials (RCTs) evaluating CM versus conventional Western therapy (CWT), or CM plus CWT versus CWT. Risk of bias and methodological quality were assessed using AGREE II, AMSTAR 2, and ROBUST-RCT tools. A total of 285 studies were included (19 CPGs/CSs, 16 SR/MAs, 250 RCTs). Evidence was most abundant for oral Chinese herbal medicine (CHM) combined with CWT and for external CHM therapies. Integrated oral CHM plus CWT generally improved disease severity, pruritus, and quality of life compared with CWT alone. External CHM therapies showed comparable or superior efficacy to topical corticosteroids, with similar or fewer adverse events. Methodological quality was heterogeneous, and outcome reporting was often incomplete. The current evidence suggests potential benefits of CM and ICWM for AD, particularly for oral CHM combined with conventional therapy and external CHM interventions. However, the overall certainty of evidence is limited by methodological weaknesses and incomplete reporting.

14 August 2025 in JMIR Research Protocols
Verified
Journal Article
Open access
ZWZijun Wang
Zijun Wang
LWLing Wang
Ling Wang
BWBingyi Wang
Bingyi Wang
HHHongfeng He
Hongfeng He
ZLZhewei Li
Zhewei Li
JEJanne Estill
Janne Estill
Background: The burden of multimorbidity is increasing globally, which complicates the use of guidelines in clinical practice and health care: practitioners may need to increasingly refer to multiple guidelines with potentially conflicting recommendations. Objective: We aim to develop a guideline-based decision support framework for the management of patients with multimorbidity to help clinicians efficiently evaluate, select, and adapt recommendations focusing on the different comorbidities and aspects of multimorbidity. Methods: We will conduct the project using the following steps: (1) needs assessment (searching published literature and documents on guideline use in multimorbidity care through the study initiators, and assessing the necessity of developing a comprehensive decision-making framework focusing on multimorbidity in a broad sense), (2) establishing international working groups (a coordination team, an evidence support group, and a consensus group) by leveraging existing participants’ networks and inviting experts with relevant academic publications or activities, (3) conducting literature reviews of multimorbidity guidelines and original qualitative research involving interest-holders in multimorbidity care and/or guideline development to formulate an initial draft framework, (4) a consensus process including an expert survey and a consensus meeting, (5) formulating and releasing the final framework, and (6) testing the framework (collecting feedback through educating health professionals in different settings and applying the framework in practice to evaluate and improve it). We plan to complete the project within 3 years. Results: The project has started in March 2024 and is due to conclude in June 2026. As of May 2025, we have finished the literature reviews and qualitative studies and are currently conducting the first round of the expert survey. Conclusions: This framework will help clinicians from all levels of health care institutions to make decisions in the management of patients with multimorbidity based on the latest available evidence, and to reduce potential health risks to their patients. One limitation of this framework is that such a broad framework may not fully fit all disease combinations or realistic situations. To reduce the degree of inapplicability, after completion of the framework, we will continue to monitor its use with regular updates as needed. International Registered Report Identifier (IRRID): DERR1-10.2196/63339

16 May 2026 in Integrative Medicine Research
Verified
Journal Article
Open access
YMYanfang Ma
Yanfang Ma
SWShouyuan Wu
Shouyuan Wu
XYXuan Yu
Xuan Yu
HLHui Liu
Hui Liu
ZWZijun Wang
Zijun Wang
ZBZhaoxiang Bian
Zhaoxiang Bian
Chinese medicine (CM) and the integrated Chinese-Western medicine (ICWM) have been recognized and commonly used in the management of rheumatoid arthritis (RA). This study aimed to leverage the AI-empowered Clinical Evidence for Integrated Chinese-Western Medicine (ACE-iMed) platform to identify clinical evidence on CM and ICWM for RA, categorize and assess it by literature type, and provide evidence summaries. Following the ACE-iMed methodology, we first constructed a dedicated literature database for RA and identified clinical questions (CQs) and outcomes of interest to clinicians in the management of RA. Furthermore, for each specific CQ, we performed target searches and screening within the database, extracted data, assessed risk of bias/methodological quality, performed data analysis and provided evidence summaries. Following literature searches and deduplication, 11,635 records were used to construct the RA and CM literature database. Across 18 questions covering ten major CM interventions and two comparisons, 556 records were ultimately identified, including 17 clinical practice guidelines/consensus statements, 35 systematic reviews, and 504 randomized controlled trials. Seven (38.9%) of the 18 CQs were supported by evidence from all three literature types. This study selected and presented evidence summaries for two CQs. Details and summaries of included studies for all CQs are available on the ACE-iMed platform. This study and relevant ACE-iMed platform provide a structured overview of clinical evidence on both CM and ICWM questions regarding RA, which can support clinicians in accessing evidence rapidly and identifying evidence distribution patterns and research gaps, and may inform future research and evidence-based practice.

17 June 2024 in JMIR Preprints
Verified
Preprint
Open access
ZWZijun Wang
Zijun Wang
LWLing Wang
Ling Wang
BWBingyi Wang
Bingyi Wang
HHHongfeng He
Hongfeng He
ZLZhewei Li
Zhewei Li
JEJanne Estill
Janne Estill
BACKGROUND The burden of multimorbidity is increasing globally, which complicates the use of guidelines in clinical practice and health care: practitioners may need to increasingly refer to multiple guidelines with potentially conflicting recommendations. OBJECTIVE We aim to develop a guideline-based decision support framework for the management of patients with multimorbidity to help clinicians efficiently evaluate, select, and adapt recommendations focusing on the different comorbidities and aspects of multimorbidity. METHODS We will conduct the project using the following steps: (1) needs assessment (searching published literature and documents on guideline use in multimorbidity care through the study initiators, and assessing the necessity of developing a comprehensive decision-making framework focusing on multimorbidity in a broad sense), (2) establishing international working groups (a coordination team, an evidence support group, and a consensus group) by leveraging existing participants’ networks and inviting experts with relevant academic publications or activities, (3) conducting literature reviews of multimorbidity guidelines and original qualitative research involving interest-holders in multimorbidity care and/or guideline development to formulate an initial draft framework, (4) a consensus process including an expert survey and a consensus meeting, (5) formulating and releasing the final framework, and (6) testing the framework (collecting feedback through educating health professionals in different settings and applying the framework in practice to evaluate and improve it). We plan to complete the project within 3 years. RESULTS The project has started in March 2024 and is due to conclude in June 2026. As of May 2025, we have finished the literature reviews and qualitative studies and are currently conducting the first round of the expert survey. CONCLUSIONS This framework will help clinicians from all levels of health care institutions to make decisions in the management of patients with multimorbidity based on the latest available evidence, and to reduce potential health risks to their patients. One limitation of this framework is that such a broad framework may not fully fit all disease combinations or realistic situations. To reduce the degree of inapplicability, after completion of the framework, we will continue to monitor its use with regular updates as needed. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/63339

20 February 2024 in JMIR Preprints
Verified
Preprint
Open access
XLXufei Luo
Xufei Luo
FCFengxian Chen
Fengxian Chen
DZDi Zhu
Di Zhu
LWLing Wang
Ling Wang
ZWZijun Wang
Zijun Wang
YCYaolong Chen
Yaolong Chen
UNSTRUCTURED Large language models (LLMs) such as ChatGPT have become widely applied in the field of medical research. In the process of conducting systematic reviews, similar tools can be used to expedite various steps, including defining clinical questions, performing the literature search, document screening, information extraction, and language refinement, thereby conserving resources and enhancing efficiency. However, when using LLMs, attention should be paid to transparent reporting, distinguishing between genuine and false content, and avoiding academic misconduct. In this viewpoint, we highlight the potential roles of LLMs in the creation of systematic reviews and meta-analyses, elucidating their advantages, limitations, and future research directions, aiming to provide insights and guidance for authors planning systematic reviews and meta-analyses.